Jin Medical Reports H1 FY2026 Net Loss of $0.2M; Revenue Down 9.7%
Jin Medical International Ltd. reported its unaudited financial results for the first half of fiscal year 2026, ending March 31, 2026. The company experienced a 9.7% decrease in total revenue to $8.9 million, primarily due to lower sales of other products and foreign exchange pressure impacting orders from its largest Japanese customer. Despite this, gross profit remained stable at $2.4 million, and gross margin improved to 26.9%. The company recorded a net loss of $0.2 million, compared to a net income of $0.01 million in the prior year period. Jin Medical emphasized its solid financial position with $9.1 million in cash and $21.0 million in short-term investments, along with increased investment in research and development for long-term growth.
Key Highlights
- Total revenue decreased 9.7% to $8.9 million for the six months ended March 31, 2026.
- Gross profit remained stable at $2.4 million for the six months ended March 31, 2026.
- Gross margin improved to 26.9% from 24.3% in the prior year period.
- Net loss was $0.2 million, compared to net income of $0.01 million year-over-year.
- Basic and diluted loss per share was $0.01 for both periods.
- Cash stood at $9.1 million and short-term investments at $21.0 million as of March 31, 2026.
- Research and development expenses increased 33.4% to $0.9 million.
- Net other income increased 344.5% to $0.5 million, driven by government grants.
Price Impact
More from ZJYL